Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers

NMR in Biomedicine

Volumn 25, Issue 11, 2012, Pages 1271-1279

  Giskeødegård, Guro F ^a   Lundgren, Steinar ^a,b   Sitter, Beathe ^a   Fjøsne, Hans E ^b   Postma, Geert ^c   Buydens, Lutgarde M C ^c   Gribbestad, Ingrid S ^a   Bathen, Tone F ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Estrogen receptor; HR MAS; Metabolomics; MRS; Multivariate analysis; NMR; PCA; PLS DA

Indexed keywords

ESTROGEN RECEPTOR; HR MAS; METABOLOMICS; MRS; MULTI VARIATE ANALYSIS; PCA; PLS-DA;

AMINO ACIDS; BIOMOLECULES; DIAGNOSIS; DISCRIMINANT ANALYSIS; DISEASES; FAULT TOLERANT COMPUTER SYSTEMS; FORECASTING; METABOLISM; METABOLITES; MULTIVARIANT ANALYSIS; NATURAL LANGUAGE PROCESSING SYSTEMS; NUCLEAR MAGNETIC RESONANCE; PRINCIPAL COMPONENT ANALYSIS; SEPARATION; TISSUE;

PATIENT TREATMENT;

ALANINE; ASCORBIC ACID; BIOLOGICAL MARKER; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; GLYCINE; LACTIC ACID; PHOSPHORYLCHOLINE; TAURINE;

ADULT; AGED; ARTICLE; BREAST BIOPSY; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL ASSESSMENT; DIAGNOSTIC TEST ACCURACY STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL LEAST SQUARES REGRESSION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT PLANNING; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; DISCRIMINANT ANALYSIS; FEMALE; GLYCINE; HUMANS; KAPLAN-MEIER ESTIMATE; LACTIC ACID; LEAST-SQUARES ANALYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; RECEPTORS, ESTROGEN; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84868123347     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2798     Document Type: Article

References (42)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer, 2010; 46: 765-781.
2. Perou C, Børresen-Dale A. Systems biology and genomics of breast cancer. Cold Spring Harb. Perspect. Biol. 2010; doi: 10.1101/cshperspect.a003293.
3. Cancer in Norway 2008. Cancer Incidence, Mortality, Survival and Prevalence in Norway. Cancer Registry of Norway: Oslo; 2009.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
5. Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. Trends Anal. Chem. 2005; 24: 285-294.
6. Andrew ER. The narrowing of NMR spectra of solids by high-speed specimen rotation and the resolution of chemical shift and spin multiplet structures for solids. Prog. Nucl. Magn. Reson. Spectrosc. 1971; 8: 1-39.
7. Sitter B, Bathen T, Tessem M, Gribbestad I. High-resolution magic angle spinning (HR MAS) MR spectroscopy in metabolic characterization of human cancer. Prog. Nucl. Magn. Reson. Spectrosc. 2009; 54: 239-254.
8. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002; 15: 327-337.
9. Bathen TF, Sitter B, Sjøbakk TE, Tessem M-B, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res. 2010; 70: 6692-6696.
10. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006; 19: 30-40.
11. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res. Treat. 2007; 104: 181-189.
12. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, Bathen TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J. Proteome Res. 2010; 9: 972-979.
13. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GAN, Owusu-Sarfo K, Ballas RA, Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010; 70: 8309-8318.
14. Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, Gribbestad IS. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010; 23: 424-431.
15. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer, 1957; 11: 359-377.
16. Eilers PHC. Parametric time warping. Anal. Chem. 2004; 76: 404-411.
17. Savorani F, Tomasi G, Engelsen SB. icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J. Magn. Reson. 2010; 202: 190-202.
18. Giskeødegård GF, Bloemberg TG, Postma G, Sitter B, Tessem M-B, Gribbestad IS, Bathen TF, Buydens LMC. Alignment of high resolution magic angle spinning magnetic resonance spectra using warping methods. Anal. Chim. Acta 2010; 683: 1-11.
19. Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics Chemometrics. Intell. Lab. Syst. 2001; 58: 109-130.
20. Keun HC, Ebbels TMD, Antti H, Bollard ME, Beckonert O, Holmes E, Lindon JC, Nicholson JK. Improved analysis of multivariate data by variable stability scaling: application to NMR-based metabolic profiling. Anal. Chim. Acta, 2003; 490: 265-276.
21. Carrola J, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L, Duarte IF. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 2010; 10: 221-230.
22. Tejler G, Norberg B, Dufmats M, Nordenskjöld B. Survival after treatment for breast cancer in a geographically defined population. Br. J. Surg. 2004; 91: 1307-1312.
23. Demicheli R, Biganzoli E, Ardoino I, Boracchi P, Coradini D, Greco M, Moliterni A, Zambetti M, Valagussa P, Gukas ID, Bonadonna G. Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci. 2010; 101: 826-30.
24. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol. 2010; 6: 127-148.
25. Yotnda P, Wu D, Swanson A. Hypoxic tumors and their effect on immune cells and cancer therapy. Methods Mol. Biol. 2010; 651: 1-29.
26. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 2010; 16: 5928-5935.
27. Mathupala S, Colen C, Parajuli P, Sloan A. Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis. J. Bioenerg. Biomembr. 2007; 39: 73-77.
28. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
29. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
30. Rivenzon-Segal D, Boldin-Adamsky S, Seger D, Seger R, Degani H. Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int. J. Cancer, 2003; 107: 177-182.
31. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000; 60: 916-921.
32. 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer. J. Magn. Reson. Imaging, 2007; 25: 992-999.
33. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 349-353.
34. 1H MRS at 1.5 Tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR. NMR Biomed. 2010; 23: 80-87.
35. Berg JM, Tymoczko JL, Stryer L. Biochemistry, 5th edn. W. H. Freeman and Company: New York; 2002.
36. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer. Cancer Res. 2002; 62: 1966-1970.
37. Moestue S, Borgan E, Huuse E, Lindholm E, Sitter B, Børresen-Dale A, Engebraaten O, Mælandsmo G, Gribbestad I. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer, 2010; 10: 433.
38. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale A-L, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature, 2000; 406: 747-752.
39. Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, Siggelkow W, Hengstler JG, Elsässer A, Gehrmann M, Lehr H-A, Koelbl H, von Minckwitz G, Harbeck N, Thomssen C. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer - comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann. Oncol. 2009; 20: 258-264.
40. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman IS. Histopathology of breast cancer in relation to age. Br. J. Cancer 1997; 75: 593-596.
41. Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J. Clin. Oncol. 2007; 25: 1683-1690.
42. Dignam J, Dukic V, Anderson S, Mamounas E, Wickerham D, Wolmark N. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res. Treat. 2009; 116: 595-602.